SOUTH SAN FRANCISCO, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies...
potential for cannabinoid-based therapies to treat neurological disorders such as Alzheimer’s disease,
The licensing agreement will expand Zelira’s interest in chronic pain treatments while it continues to develop its insomnia and autism spectrum disorder candidates.
Zelira Therapeutics has reported positive data from the Phase Ia/IIb clinical trial of medicinal cannabis for the treatment of insomnia.